Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study.
Gragnani L, Fabbrizzi A, Triboli E, Urraro T, Boldrini B, Fognani E, Piluso A, Caini P, Ranieri J, Monti M, Laffi G, Zignego AL.
Dig Liver Dis. 2014 Sep;46(9):833-7. doi: 10.1016/j.dld.2014.05.017. Epub 2014 Jun 19.
Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.
Saxena V, Manos MM, Yee HS, Catalli L, Wayne E, Murphy RC, Shvachko VA, Pauly MP, Chua J, Monto A, Terrault NA.
Aliment Pharmacol Ther. 2014 May;39(10):1213-24. doi: 10.1111/apt.12718. Epub 2014 Mar 24.
Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.
Helal GK, Gad MA, Abd-Ellah MF, Eid MS.
J Med Virol. 2016 Dec;88(12):2170-2178. doi: 10.1002/jmv.24575. Epub 2016 May 25.
The effect of direct acting antiviral agents on vascular endothelial function in Egyptian patients with chronic hepatitis C virus infection.
Freekh DA, Helmy MW, Said M, El-Khodary NM.
Saudi Pharm J. 2021 Oct;29(10):1120-1128. doi: 10.1016/j.jsps.2021.08.006. Epub 2021 Aug 4.
Triple Threat: Triple Pathogen Endocarditis.
Gonzalez JM, Lowenhaar G, Ramgopal M, Chalasani P.
Cureus. 2023 Oct 28;15(10):e47860. doi: 10.7759/cureus.47860. eCollection 2023 Oct.
Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions.
Teixeira R, Nascimento Yde A, Crespo D.
Braz J Infect Dis. 2013 Mar-Apr;17(2):194-204. doi: 10.1016/j.bjid.2012.10.010. Epub 2013 Mar 9.
Management of side-effects.
Rosa I.
Clin Res Hepatol Gastroenterol. 2011 Dec;35 Suppl 2:S69-74. doi: 10.1016/S2210-7401(11)70011-0.
Evaluation of telaprevir-containing triple therapy in the treatment of chronic hepatitis C in hemodialysed patients.
Kaya S, Aksoz S, Baysal B, Ay N, Danis R.
Infect Dis (Lond). 2015 Sep;47(9):658-61. doi: 10.3109/23744235.2015.1034769. Epub 2015 May 2.
Chronic hepatitis C genotype 1 virus: who should wait for treatment?
Tovo CV, de Mattos AA, de Almeida PR.
World J Gastroenterol. 2014 Mar 21;20(11):2867-75. doi: 10.3748/wjg.v20.i11.2867.
Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis.
Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Akahoshi T, Maehara Y, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.
J Gastroenterol Hepatol. 2014 Sep;29(9):1728-35. doi: 10.1111/jgh.12619.
